Aptose Biosciences Inc. (NASDAQ:APTO) Sees Significant Decline in Short Interest

Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) was the recipient of a significant drop in short interest during the month of March. As of March 15th, there was short interest totalling 53,200 shares, a drop of 56.6% from the February 28th total of 122,600 shares. Based on an average daily trading volume, of 395,000 shares, the short-interest ratio is presently 0.1 days. Currently, 3.3% of the shares of the stock are short sold.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and set a $60.00 target price on shares of Aptose Biosciences in a research note on Wednesday, February 12th. StockNews.com assumed coverage on Aptose Biosciences in a research report on Thursday. They set a “sell” rating for the company. Finally, Alliance Global Partners upgraded Aptose Biosciences to a “strong-buy” rating in a research report on Thursday, February 27th. One analyst has rated the stock with a sell rating, three have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Aptose Biosciences has an average rating of “Moderate Buy” and an average price target of $130.00.

Aptose Biosciences Trading Up 6.0 %

Shares of NASDAQ APTO opened at $3.70 on Friday. Aptose Biosciences has a 12-month low of $2.39 and a 12-month high of $51.61. The firm’s 50-day moving average price is $4.63 and its 200-day moving average price is $7.59. The stock has a market capitalization of $7.92 million, a price-to-earnings ratio of -1.25 and a beta of 1.14.

Institutional Investors Weigh In On Aptose Biosciences

An institutional investor recently bought a new position in Aptose Biosciences stock. Bleichroeder LP purchased a new position in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 2,500,000 shares of the biotechnology company’s stock, valued at approximately $563,000. Bleichroeder LP owned 4.15% of Aptose Biosciences as of its most recent filing with the Securities and Exchange Commission (SEC). 26.62% of the stock is owned by hedge funds and other institutional investors.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.